Literature DB >> 11081192

Are markers of proliferation valuable in the histological assessment of pituitary tumours?

H E Turner1, J A Wass.   

Abstract

The prediction of tumour behaviour and response to treatment has led to interest in the assessment of the proliferative potential of tumours. Pituitary tumours are usually histologically benign but are capable of aggressive growth and local invasion, although distant metastasis is limited to the very rare pituitary carcinoma. These differences in tumour behaviour may determine both the prognosis and also the effectiveness of treatment whether it be surgery, drugs or radiotherapy. Immunohistochemistry using antibodies to Ki-67 and proliferating cell nuclear antigen (PCNA) which are expressed in cells that have entered the cell cycle, can be used to assess the proportion of the cells from a tumour that are proliferating. The percentage of positively stained nuclei (labelling index (LI)) may be helpful in predicting appropriate management, as there is a relationship in many tumours between labelling index, invasiveness and tumour recurrence. This has been shown to be true for pituitary tumours, although there may be significant overlap such that low LI may be seen in the rare, aggressive, metastatic pituitary carcinomas, and high LI in indolent tumours. Thus although assessment of proliferation may be helpful in arousing suspicion as to subsequent tumour recurrence or invasiveness, this technique also demonstrates that there are other important and as yet unidentified processes that determine pituitary tumour behaviour.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11081192     DOI: 10.1023/a:1009979128608

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  31 in total

1.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

Review 2.  Monoclonal antibody Ki-67: its use in histopathology.

Authors:  D C Brown; K C Gatter
Journal:  Histopathology       Date:  1990-12       Impact factor: 5.087

3.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.

Authors:  E Delgrange; J Trouillas; D Maiter; J Donckier; J Tourniaire
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

4.  Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study.

Authors:  D N Louis; S Edgerton; A D Thor; E T Hedley-Whyte
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

5.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

6.  Flow cytometry analysis of pituitary adenomas.

Authors:  O Fornas; M E Mato; M Viader; B Oliver; P Tresserres; F Bartumeus; D Tugues; J Pétriz; X Matías-Guiu; S M Webb
Journal:  Horm Res       Date:  1996

7.  Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67.

Authors:  E Knosp; K Kitz; A Perneczky
Journal:  Neurosurgery       Date:  1989-12       Impact factor: 4.654

8.  Invasiveness of pituitary adenomas.

Authors:  D Sautner; W Saeger
Journal:  Pathol Res Pract       Date:  1991-06       Impact factor: 3.250

9.  Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67.

Authors:  P Zuber; M F Hamou; N de Tribolet
Journal:  Neurosurgery       Date:  1988-02       Impact factor: 4.654

10.  Ras mutations in human pituitary tumors.

Authors:  H J Karga; J M Alexander; E T Hedley-Whyte; A Klibanski; J L Jameson
Journal:  J Clin Endocrinol Metab       Date:  1992-04       Impact factor: 5.958

View more
  18 in total

1.  Determination of cell proliferation using Mcm2 antigen and evaluation of apoptosis and TGF-beta1 expression in GH-secreting or clinically nonfunctioning pituitary adenomas.

Authors:  Cristina Micheletto Dallago; Ligia Maria Barbosa-Coutinho; Nelson Pires Ferreira; Rosalva Meurer; Julia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

Review 2.  Update on prognostic factors in acromegaly: Is a risk score possible?

Authors:  E Fernandez-Rodriguez; F F Casanueva; I Bernabeu
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

3.  Differential DNA methylome profiling of nonfunctioning pituitary adenomas suggesting tumour invasion is correlated with cell adhesion.

Authors:  Ye Gu; Xinyao Zhou; Fan Hu; Yong Yu; Tao Xie; Yuying Huang; Xinzhi Zhao; Xiaobiao Zhang
Journal:  J Neurooncol       Date:  2016-05-11       Impact factor: 4.130

4.  Pituitary function and morphology in Fabry disease.

Authors:  Luigi Maione; Fabio Tortora; Roberta Modica; Valeria Ramundo; Eleonora Riccio; Aurora Daniele; Maria Paola Belfiore; Annamaria Colao; Antonio Pisani; Antongiulio Faggiano
Journal:  Endocrine       Date:  2015-04-21       Impact factor: 3.633

5.  Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas.

Authors:  Erica Hightower; Maria E Cabanillas; Greg N Fuller; Ian E McCutcheon; Kenneth R Hess; Komal Shah; Steven G Waguespack; Lynda J Corley; Jessica K Devin
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

6.  Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space.

Authors:  Li-Xiong Pan; Zhong-Ping Chen; Yun-Sheng Liu; Ji-Hong Zhao
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

7.  Apoptosis is increased and cell proliferation is decreased in out-of-phase endometria from infertile and recurrent abortion patients.

Authors:  Gabriela F Meresman; Carla Olivares; Susana Vighi; Margarita Alfie; Marcela Irigoyen; Juan J Etchepareborda
Journal:  Reprod Biol Endocrinol       Date:  2010-10-22       Impact factor: 5.211

8.  Postcoital administration of asoprisnil inhibited embryo implantation and disturbed ultrastructure of endometrium in implantation window in mice.

Authors:  Xiao-Li Wu; Zhi-Hong Yu; Jun Qiu; Yi-Hong Yang; Xiao-Li Shen; Ping Su
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17

Review 9.  Best Practice No 172: pituitary gland pathology.

Authors:  J W Ironside
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

10.  Immunolocalization of Pit-1 in gonadotroph nuclei is indicative of the transdifferentiation of gonadotroph to lactotroph cells in prolactinomas induced by estrogen.

Authors:  Jorge Humberto Mukdsi; Ana Lucía De Paul; Sonia Muñoz; Agustín Aoki; Alicia Inés Torres
Journal:  Histochem Cell Biol       Date:  2004-06-09       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.